Evidence map›Paper›PMID 38612615›Full record

ReviewInternational journal of molecular sciences2024

Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition.

Noemi Cárdenas-Rodríguez, Iván Ignacio-Mejía, Jose Correa-Basurto, Humberto Carrasco-Vargas, Marco Antonio Vargas-Hernández, Exal Manuel Albores-Méndez, Rodolfo David Mayen-Quinto, Reynita De La Paz-Valente, Cindy Bandala

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Noemi Cárdenas-RodríguezLaboratorio de Neurociencias, Instituto Nacional de Pediatría, Mexico City 04530, Mexico.ORCID 0000-0002-6580-3440
Iván Ignacio-MejíaLaboratorio de Medicina Traslacional, Escuela Militar de Graduados de Sanidad, UDEFA, Mexico City 11200, Mexico.ORCID 0000-0003-3792-4613
Jose Correa-BasurtoLaboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0002-4973-5265
Humberto Carrasco-VargasDirección de la Escuela Militar de Graduados de Sanidad, UDEFA, Mexico City 11200, Mexico.
Marco Antonio Vargas-HernándezSubdirección de Investigación, Escuela Militar de Graduados en Sanidad, UDEFA, Mexico City 11200, Mexico.ORCID 0000-0002-2518-2803
Exal Manuel Albores-MéndezSubdirección de Investigación, Escuela Militar de Graduados en Sanidad, UDEFA, Mexico City 11200, Mexico.
Rodolfo David Mayen-QuintoLaboratorio de Biología Molecular, Escuela Militar de Graduados en Sanidad, Mexico City 11200, Mexico.
Reynita De La Paz-ValenteLaboratorio de Medicina Traslacional Aplicada a Neurociencias, Enfermedades Crónicas y Emergentes, Escuela superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Cindy BandalaLaboratorio de Medicina Traslacional Aplicada a Neurociencias, Enfermedades Crónicas y Emergentes, Escuela superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0002-7414-2621
Universidad del Ejército y Fuerza Aérea · MXInstituto Politécnico Nacional · MXHospital Central Militar · MXInstituto Nacional de Pediatria · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, and treatment is crucial. Neuroinflammation causes the most common manifestations of this disease including headaches, fatigue, insomnia, depression, anxiety, among others. Currently, there are no specific management proposals; however, given that the inflammatory component involves cytokines and free radicals, these conditions must be treated to reduce the current symptoms and provide neuroprotection to reduce the risk of a long-term neurodegenerative disease. It has been shown that cannabis has compounds with immunomodulatory and antioxidant functions in other pathologies. Therefore, exploring this approach could provide a viable therapeutic option for PCC, which is the purpose of this review. This review involved an exhaustive search in specialized databases including PubMed, PubChem, ProQuest, EBSCO, Scopus, Science Direct, Web of Science, and Clinical Trials. Phytocannabinoids, including cannabidiol (CBD), cannabigerol (CBG), and Delta-9-tetrahydrocannabinol (THC), exhibit significant antioxidative and anti-inflammatory properties and have been shown to be an effective treatment for neuroinflammatory conditions. These compounds could be promising adjuvants for PCC alone or in combination with other antioxidants or therapies. PCC presents significant challenges to neurological health, and neuroinflammation and oxidative stress play central roles in its pathogenesis. Antioxidant therapy and cannabinoid-based approaches represent promising areas of research and treatment for mitigating adverse effects, but further studies are needed.

Indexed as

CannabisCOVID-19HallucinogensNeurodegenerative DiseasesAntioxidantsCannabinoid Receptor AgonistsHumansNeuroinflammatory DiseasesPost-Acute COVID-19 SyndromeAntioxidantsCannabinoid Receptor AgonistsHallucinogensantioxidantcannabisneuroinflammationpost-COVID-19 condition

Identifiers

PMID38612615
PMCPMC11012123
OpenAlexW4393950739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.